Objectives: Information on the efficacy of extended meropenem administration in neutropenic patients is scarce. Our objective was to determine whether the administration of meropenem in a 4 h extended infusion (EI) leads to a better clinical outcome in patients with febrile neutropenia than the conventional short infusion (SI).
Introduction
The pharmacokinetic (PK) and pharmacodynamic (PD) profile of meropenem has been thoroughly investigated in the last decade and has gained special interest since PK/PD-driven therapeutic strategies became a focus of attention of antimicrobial research. The efficacy of meropenem is positively correlated with the time over which free-drug serum concentrations remain above the MIC (fT .MIC ) 1,2 and its bactericidal activity becomes optimal above concentrations of 4 -6×MIC. 3, 4 It is widely accepted that the desirable PD target for carbapenems to achieve bactericidal activity is 40% fT .MIC , although the supportive evidence is mainly based on animal studies. 5 -7 On the other hand, others have suggested that an even higher fT .MIC is needed for the optimal antibiotic treatment of immunocompromised patients-such as critically ill or neutropenic patients. 8 -11 Another study on febrile neutropenia concluded that the higher the fT .MIC , the better the clinical outcome. 12 By prolonging the infusion times for b-lactams the magnitude of %T .MIC increases, 11, 13 which is of special interest in neutropenic patients, given their seriously impaired immunological state and altered PK.
14 However, the clinical evidence in this setting is scarce; the original articles published in this field during the last 20 years are retrospective case series 15, 16 or studies with PK/PD or safety parameters as their primary objectives. 17 -19 # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2014; 69: 2556 -2562 doi:10.1093/jac/dku150 Advance Access publication 22 May 2014 Meropenem has a well-established role in the empirical treatment of patients with febrile neutropenia. 20, 21 The objective of this study was to determine whether the administration of meropenem in a 4 h extended infusion (EI) leads to a more favourable clinical outcome in patients with febrile neutropenia compared with the conventional 30 min short infusion (SI).
Patients and methods

Study population and data collection
This single-centre, retrospective, pre -post observational study was conducted in the haematology department of a 700 bed Spanish university hospital. The subjects were recipients of haematopoietic stem-cell transplantation (HSCT) or patients treated with induction chemotherapy for acute myeloid leukaemia (AML) between 1 April 2007 and 31 March 2010, who were receiving meropenem as monotherapy or in combination with a glycopeptide and/or an aminoglycoside as empirical antibiotic therapy during the neutropenic phase of the treatment. Fever was defined as a peripheral body temperature ≥37.58C. Patients without fever at the time of the start of antibiotic treatment were excluded, as were those with impaired renal function (defined as a CL CR ,50 mL/min) that implied antibiotic dosage adjustments.
An unblinded revision of the clinical history of each patient was carried out to assess the baseline characteristics as well as clinical, laboratory and microbiological data. The peripheral body temperature of the patients was registered every 6 h, and data on daily complete blood count and C-reactive protein (CRP) levels during the 10 days following fever onset were also available.
Febrile episodes were catalogued as microbiologically documented infections with or without bacteraemia, fever of non-infectious aetiology and probable infections without microbiological evidence (in the absence of positive microbiological data or other evident non-infectious causes).
Until 30 September 2008 the applied dose of meropenem was 1 g/8 h administered in SI in a 100 mL physiological saline solution, and from 1 October 2008 onward the same dose in the same dilution was administered in EI. The infusion time was calculated on a drops-per-minute basis in every case. The 4 h infusion time in patients receiving meropenem in EI was occasionally reduced for a given dose because of lack of availability of venous access in polymedicated patients, and this was registered in the clinical history.
Because of the retrospective observational design of the study, according to our Ethics Committee, neither patient consent nor ethics approval was required at our hospital at the time the study was carried out.
Endpoints and data analysis
The primary endpoint was the success of the empirical antibiotic therapy after 5 days of treatment. Treatment success was defined as: (i) a drop of body temperature to ,37.58C leading to a ≥24 h feverless state (henceforth referred to as defervescence); (ii) the resolution or improvement of the clinical signs and symptoms of infection when there had been any; (iii) the absence of persistent or breakthrough bacteraemia; and (iv) no additional antibiotic treatment introduced because of an unsatisfactory clinical evolution. Treatment failure was defined as the failure to fulfil any of these criteria. Secondary endpoints were: (i) the time (h) of defervescence; (ii) the time (days) until CRP levels descended to ,5 mg/dL or to ,50% of their initial value (defined as the higher of two determinations on the first 2 days of treatment); (iii) the length of hospital stay (LOS); and (iv) 100 day mortality.
After analysing the study population as a whole (analysis I), the analysis was repeated on three subgroups obtained by: (II) excluding episodes of clearly non-infectious origin; (III) furthermore excluding the infections caused by meropenem-resistant microorganisms; and (IV) selecting only patients treated with meropenem as monotherapy.
Statistical analysis was performed using the statistical software SPSS (version 19.0). The comparison of the study groups in the case of binary variables was carried out using the x 2 test and Fisher's exact test in the case of a violation of application criteria of the former; for continuous variables the Student's t-test was used and-in the absence of a normal distribution-the Mann-Whitney U-test was employed. Data on defervescence and the evolution of CRP values were analysed using Kaplan-Meier survival curves obtaining P values by means of the log-rank test, and to determine the factors associated with a positive clinical outcome a multivariate analysis by backward stepwise logistic regression was carried out on basic demographic data (sex and age) and variables significant at a P value of ≤0.2 in the univariate analysis.
Results
During the study period, 175 patients with febrile neutropenia were treated with meropenem. Eleven of these were excluded for meeting the exclusion criteria: 10 patients for absence of fever and one patient for impaired renal function. Of the remaining 164 subjects, 88 received meropenem in SI and 76 in EI.
No significant differences were found in the baseline characteristics of the two groups ( Table S1 and Table S2 (both available as Supplementary data at JAC Online).
In the EI group, 18/76 patients (23.7%) received some of the meropenem doses in ,4 h due to technical reasons, the mean infusion time per dose during the first 2 days of treatment being 3.62 h (SD 0.41) in this group. The mean daily meropenem infusion time during the 10 days of follow-up was 11.5 h (SD 1.51). The initial antibiotic regimen had to be modified by day 5 in 44/88 (50.0%) cases and in 20/76 (26.3%) cases in the SI and EI groups, respectively (P ¼ 0.002).
After 5 days of treatment, antibiotic therapy was successful in significantly more cases in the EI group than in the SI group [52/76 (68.4%) versus 36/88 (40.9%); P ¼ 0.001]. The results of the univariate analysis of factors associated with treatment success at day 5 are shown in Table 2 . According to the multivariate analysis, meropenem administered in EI was the only variable significantly related to therapeutic success (OR 3.13, 95% CI 1.61-6.10), while the presence of severe mucositis or a non-catheter infectious focus were associated with treatment failure (OR 0.24, 95% CI 0.08-0.79 and OR 0.46, 95% CI 0.22 -0.95, respectively).
Significant differences favouring the EI group were found by Kaplan -Meier survival analysis, regarding time to defervescence and time to descent of CRP to ,5 mg/dL or to ,50% of its initial value (Figure 1 ). Differences in LOS and mortality rate did not reach statistical significance (Table 3) .
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The results of the subgroup analyses II to IV were similar to the data presented above (see Table S3, Table S4 and Figure S1 , all available as Supplementary data at JAC Online). Table 4 summarizes the results of the four multivariate analyses.
Discussion
To our knowledge this is the first study that has evaluated the effect of meropenem administered in EI on the clinical evolution of neutropenic patients with fever. Meropenem administered in EI led to a higher therapeutic success rate and an earlier response to treatment than the SI method, which resulted in a lower additional antibiotic prescription rate in the EI group. There was, however, no significant difference in LOS or in the 100 day mortality rate between the study groups.
The administration of the same dose of b-lactams in extended or continuous infusion increases both the percentage of patients who achieve a certain fT .MIC and the magnitude of fT .MIC . 11, 13, 22, 23 Hence one would expect better clinical results by applying these drug administration methods. However, despite the promising results reported in some series, 24 -26 the majority of the meta-analyses could not corroborate a beneficial effect of alternative antibiotic administration strategies in terms of clinical outcomes. 27 -30 In fact only two meta-analyses have reported data in favour of extended or continuous antibiotic administration. The first demonstrated a lower failure rate with continuous infusion, analysing a group of five studies in which equal antibiotic doses were used in both the arms. 31 The other meta-analysis found a lower mortality rate among patients with Gram-negative sepsis who received meropenem and piperacillin/tazobactam in extended or continuous infusion. 32 The study groups showed minor differences in their general characteristics and the discrepancies tended to affect the EI group negatively. The increased rate of ALHSCT among these patients implied a deeper and longer immunosuppression and additional post-transplant complications that could have led to more severe infections and higher mortality. 33 -35 Nevertheless, 27.5% more favourable outcomes were observed after 5 days of treatment in this group than in the SI group.
Microbiological evidence of infection was found in 32% of cases-in accordance with other studies reporting an absence of microbiological evidence in around 30% -60% of episodes of febrile neutropenia. 36, 37 However, given the clinical benefit of extended meropenem infusion that was observed, it is reasonable to speculate that an important proportion of febrile episodes with negative cultures were nevertheless caused by bacteria-most of them meropenem susceptible.
In the multivariate analyses performed on subgroups of the study population the more homogeneous the set of patients were, the stronger the association between the EI and treatment success became. This became even more evident in the subgroup of patients treated with meropenem as monotherapy, where no empirical glycopeptide treatment was indicated (i.e. no Grampositive infection was suspected, as in patients with severe oral mucositis, infected catheter insertion site, skin infections, etc.)-presumably because of a lower Gram-positive/Gram-negative ratio in this subgroup.
Although no deaths occurred during the first 10 days of treatment and no significant differences were observed in the medium-term mortality, a faster or slower response rate to antibiotic therapy is not without consequences. Patients in the EI group showed a more prompt improvement as demonstrated Extended meropenem infusion in febrile neutropenia by the evolution of body temperature, as a clinical marker of infection, and the evolution of CRP levels, as a biochemical marker of infection. A slower response may explain why almost two times as many patients were prescribed additional antimicrobial medication in the SI group compared with the patients in the EI group. This usually consisted of the addition of vancomycin, amikacin or an antifungal drug such as amphotericin B, voriconazole or an echinocandin, and the possible adverse effects and price of these agents are prone to making patient care longer, less safe and more costly. 38 -40 Again, in the subgroup of patients treated with meropenem as monotherapy, this relation was even more evident.
The study has some important limitations to be taken into consideration. Its observational design did not allow control of all the confounding variables and potentially made the study vulnerable to selection bias. The pre-post design inherently entails a certain grade of time bias, although we believe it to be minimal in our case because of the close temporal proximity of the two groups and because no significant changes took place in patient care protocols, ward personnel or infrastructure in our haematology department during the 3 years embraced by the study. On the other hand, the pre -post design prevented prescription bias, a not infrequent error with contemporaneous cohorts. The absence of blinding at data collection could potentially have been a source Fehér et al.
of observer bias, although the majority of the outcomes evaluated were objective data. No data on the serum levels of meropenem were available to support the causal sequence of prolonged antibiotic infusion to higher fT .MIC to better outcome. Finally, in the absence of data on adverse effects and acquired bacterial resistance no conclusions could be drawn on these controversial issues either. 29, 41 In light of our results, meropenem administration in a 4 h EI may result in a better clinical outcome for febrile episodes of neutropenia, with a faster resolution of fever and a more prompt decline in CRP levels. This phenomenon may have important consequences for the need for additional antibiotic therapy, with all its implications in terms of patient safety and economics. Adequately designed randomized clinical trials are warranted to validate our results that should preferably assess safety and economic aspects as well as to offer a more complete picture of this complex issue.
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